Clinical trials: Nephritis
Autoimmune Disorders, Systemic Sclerosis
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
The goal of Safety Lead-In is to confirm the safety of tafasitamab when given to patients with SSc, SLE, and LN. The goal of Phase 1 is to find the recommended dose of AD-PluReceptor-NK cells in combination with tafasitamab and…
- Conditions
- Autoimmune Disorders, Systemic Sclerosis, Systemic Lupus Erythematosus, Lupus
- Trial name
- NCT06434363
- Testing
- Tafasitamab, Fludarabine phosphate, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- M.D. Anderson Cancer Center
Lupus Nephritis
Anti-alpha-actinin Antibodies and Lupus Nephritis Activity
Lupus nephritis (LN) develops in 30-60% of systemic lupus erythematosus (SLE) patients and remains a leading cause of morbidity, with 10-30% progressing to end-stage renal disease within 15 years.
- Trial name
- NCT07505576
- Testing
- renal biopsy, serum anti-alpha-actinin antibodies, CBC, serum creatinine and urea, estimated GFR, ESR, CRP, urine analysis, ANA, anti dsDNA, C3 & C4, serum albumin, 24-hrs urinary protein, and U. ACR
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Assiut University
Lupus Nephritis
Assess the Efficacy and Safety of Multi-target Therapy in Lupus Nephritis
The purpose of this study is to assess the efficacy and safety of multi-target therapy in the treatment of class Ⅲ,Ⅳ,Ⅴ,Ⅲ+Ⅴand Ⅳ+Ⅴ lupus nephritis.
- Trial name
- NCT00876616
- Testing
- Tacrolimus+Mycophenolate mofetil, Cyclophosphamide
- Where
- China
- Volunteers
- 362 people
- Sponsor
- Zhi-Hong Liu, M.D.
Urinary Tract Infection, Pyelonephritis
Risk Factors for Recurrent Urinary Tract Infection in Children
The purpose of this study is to determine clinical and urodynamic risk factors for recurrent urinary tract infection in 5-18 years old children.
- Conditions
- Urinary Tract Infection, Pyelonephritis, Cystitis
- Trial name
- NCT00528476
- Where
- Lithuania
- Volunteers
- 161 people
- Sponsor
- Kaunas University of Medicine
Lupus Nephritis
Efficiency of Use of Baracetinib in Treatment of Lupus Nephritis
Patients with systemic lupus erythematosus have substantial unmet medical need. Baricitinib is an oral selective Janus kinase (JAK)1 and JAK2 inhibitor that we hypothesised might have therapeutic benefit in patients with systemic…
- Trial name
- NCT05432531
- Testing
- Anti JAK1,2, Cyclophosphamid
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Assiut University
Primary Membranous Nephropathy
A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy
The goal of the Phase 3a part of this clinical trial is to determine the optimal dose that will be used in the Phase 3b part of this clinical trial.
- Trial name
- NCT05696613
- Testing
- SNP-ACTH (1-39) Gel, Rituximab
- Where
- 31 sites in United States, Canada and 1 more
- Volunteers
- 148 people
- Sponsor
- Cerium Pharmaceuticals, Inc.
Systemic Lupus Erythematosus, Lupus Nephritis
Epigenetics in Lupus Nephritis
This is a translational study for the identification of epigenetic changes detectable in sera of patients suffering from Systemic Lupus erythematosus.
- Trial name
- Epi_LN (NCT04648059)
- Testing
- Blood sampling
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- University of Göttingen
Lupus Nephritis
Zanubrutinib in Participants With Active Proliferative Lupus Nephritis
The primary objective of this study is to evaluate the efficacy of zanubrutinib added to standard of care as measured by complete renal response for participants with active proliferative lupus nephritis
- Trial name
- NCT04643470
- Testing
- Zanubrutinib
- Where
- 44 sites in China
- Volunteers
- 177 people
- Sponsor
- BeiGene
Immunoglobulin A Nephropathy
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
The purpose of this study is to evaluate the efficacy of povetacicept in adult participants compared with placebo in reducing proteinuria and preserving renal function.
- Trial name
- NCT06564142
- Testing
- Povetacicept
- Where
- 318 sites in United States, Australia and 31 more
- Volunteers
- 605 people
- Sponsor
- Alpine Immune Sciences Inc, A Subsidiary of Vertex
Lupus Nephritis
Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN)
The purpose of this study is to characterize the safety and tolerability of ixazomib when administered as multiple oral doses at escalating dose levels in participants with lupus nephritis.
- Trial name
- NCT02176486
- Testing
- Ixazomib
- Where
- 35 sites in United States, France and 5 more
- Volunteers
- 12 people
- Sponsor
- Takeda
Lupus Nephritis
Fixed-dose Versus Concentration-controlled Mycophenolate Mofetil for the Treatment of Active Lupus Nephritis
A randomized open-label study of fixed-dose versus concentration-controlled mycophenolate mofetil for treatment of active lupus nephritis.
- Trial name
- NCT03920059
- Testing
- Mycophenolate Mofetil
- Where
- Thailand
- Volunteers
- 2 people
- Sponsor
- Chulalongkorn University
C3G, IC-MPGN
C3G/Primary IC-MPGN EAP
This is an Early Access Program (EAP) which will provide access to pegcetacoplan for eligible participants with C3G and Primary IC-MPGN.
- Conditions
- C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis
- Trial name
- NCT04729062
- Testing
- Pegcetacoplan
- Sponsor
- Apellis Pharmaceuticals, Inc.
Emphysematous Pyelonephritis
Factors Associated To Intensive Care Admission And Mortality In Patients With Emphysematous Pyelonephritis
Emphysematous pyelonephritis is a lifethreatening necrotizing infection of the kidney characterized by accumulation of gas in the renal parenchyma and within the surrounding tissues.
- Trial name
- NCT04326517
- Testing
- Nephrectomy
- Where
- Mexico
- Volunteers
- 65 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
IgA Nephropathy
A Controlled Study of Uric Acid on the Progression of IgA Nephropathy
This prospective, randomized controlled study will evaluate the effect of uric acid on the progression of IgA nephropathy.
- Trial name
- NCT00793585
- Testing
- allopurinol, continue their usual therapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Focal Segmental Glomerulosclerosis
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of praliciguat in adults with biopsy-confirmed focal segmental glomerulosclerosis (FSGS).
- Trial name
- NCT07268638
- Testing
- Praliciguat (Part A), Praliciguat (Part B)
- Where
- 30 sites in United States
- Volunteers
- 60 people
- Sponsor
- Akebia Therapeutics
Covid19
PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V
COVID-19 (SARS-CoV2 virus) was declared a global pandemic by the WHO on 11th March 2020. Currently there are no drugs proven to prevent COVID-19 or to reduce the severity of illness if given as prophylaxis.
- Trial name
- PROTECT-V (NCT04870333)
- Testing
- Niclosamide, Ciclesonide, Sotrovimab
- Where
- 45 sites in United Kingdom
- Volunteers
- 2,240 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Systemic Lupus Erythematosus
Prediction of Outcome of Lupus Nephritis
The purpose of this study is to clarify the mechanisms involved in the formation and glomerular deposition of immune complexes in lupus nephritis.
- Trial name
- NCT02403115
- Testing
- Serum collection
- Where
- Italy
- Volunteers
- 800 people
- Sponsor
- Istituto Giannina Gaslini
Refractory Membranous Nephropathy
Safety and Efficacy of CD19 Chimeric Antigen Receptor T-Cell (CAR-T) in the Treatment of Refractory Membranous Nephropathy
This study is a single-center, prospective, exploratory Phase I clinical trial initiated by the team led by Associate Professor He Lijie from the Department of Nephrology, Xijing Hospital.
- Trial name
- NCT07266181
- Testing
- All patients will receive CD19 CAR-T cell therapy on the basis of standard symptomatic and supportive treatment.
- Where
- China
- Volunteers
- 5 people
- Sponsor
- The First Affiliated Hospital of Air Force Medical University
Systemic Lupus Erthematosus (SLE), Lupus Nephritis (LN)
A Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune Diseases
This is an investigator-initiated, open-label, single-arm, dose-escalation and dose-expansion study to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of MTM-H-001 in adult participants with B-cell-related…
- Conditions
- Systemic Lupus Erthematosus (SLE), Lupus Nephritis (LN), Multiple Sclerosis, Myasthenia Gravis (MG)
- Trial name
- ArchAid-002 (NCT07593911)
- Testing
- MTM-H-001 Injection
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Beijing GoBroad Hospital
Glomerulonephritis Acute
Urinary T Cell Biomarker for Prediction in ANCA Glomerulonephritis
Urinary T lymphocytes may be predictive for clinical outcome in patients with ANCA associated glomerulonephritis (ANCA GN). The investigators hypothesize that the amount of CD4+ effector/memory T cells in urine at time of…
- Trial name
- NCT04320667
- Testing
- Flow cytometry analysis of urine samples
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 79 people
- Sponsor
- Charite University, Berlin, Germany